TRVI – trevi therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Trevi Therapeutics: Late-Stage Transition Meets Execution Risk [Seeking Alpha]
Trevi Therapeutics (TRVI) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $19.00 price target on the stock.
Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
Trevi Therapeutics launches $150M public stock offering [Seeking Alpha]
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
Form 424B5 Trevi Therapeutics, Inc.
Form 8-K Trevi Therapeutics, Inc. For: Apr 16
Form 424B5 Trevi Therapeutics, Inc.
Form PRE 14A Trevi Therapeutics, Inc. For: Apr 10
Form SCHEDULE 13G/A Trevi Therapeutics, Inc. Filed by: VANGUARD GROUP INC
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.